Phaseline

Targets › GLA

GLA (Alpha-galactosidase A): drug programs, companies and trials

5 programs from 5 companies in 8 trials: 3 Phase 1, 2 Phase 2, 2 Phase 3, 1 Phase 4; Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.

Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome. (UniProt, P06280)

Open in Phaseline: the race on GLA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaReplagal
alpha-galactosidase A (agalsidase alfa) enzyme replacement therapy
GLAPhase 4Fabry DiseaseOct 2027
Amicus TherapeuticsMigalastat
Alpha-galactosidase A stabiliser
GLAPhase 3Fabry DiseaseDec 2026
Chiesi FarmaceuticiPRX-102
Recombinant human alpha galactosidase-A (pegunigalsidase alfa)
GLAPhase 2Fabry DiseaseOct 2027
UniQure BiopharmaAMT-191
AAV5-based gene therapy delivering human α-galactosidase A
GLAPhase 1Fabry DiseaseDec 2027
4D Molecular Therapeutics4D-310
AAV gene therapy encoding codon-optimized human GLA transgene
GLAPhase 1Fabry DiseaseJun 2030

Conditions

Fabry Disease (8)

Modalities

protein or peptide (3), small molecule (2)

Companies

UniQure Biopharma (1) Chiesi Farmaceutici (1) Amicus Therapeutics (1) Takeda (1) 4D Molecular Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.